Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2016

01.12.2016 | editorial

ASCO update 2016

verfasst von: Wolfgang Eisterer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Summary

The past few years have seen major progress in cancer research and treatment. Today we are able to select treatments based on molecular profiling of tumors and do not solely rely on tumor type and stage. The most recent advance has taken place in the field of immunotherapy, and at this year’s ASCO again a huge number of studies were reported dealing with immunotherapy. In Europe we expect approval of different immunotherapies in various entities ranging from head and neck cancer, urothelial cancer, gastric cancer to lung cancer and colorectal cancer. But immunotherapy is not the only area of progress. There are tremendous advances in surgery, chemotherapy and targeted agents, too, as will be discussed in further detail in this report of the most important abstracts of this year’s ASCO by our experts in the field Drs. Wöll, Bartsch, Pall, Roider-Schur, Hamacher, Brodowicz, Kacirek, and myself.
Literatur
1.
Zurück zum Zitat Verheij M, Jansen EPM, Cats A, et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. J Clin Oncol. 2016;34(suppl):abstract 4000.CrossRef Verheij M, Jansen EPM, Cats A, et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. J Clin Oncol. 2016;34(suppl):abstract 4000.CrossRef
2.
Zurück zum Zitat Kang Y‑H, Shah MA, Ohtsu A, et al. A randomized, open label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol. 2016;34(suppl4S):abstract 5.CrossRef Kang Y‑H, Shah MA, Ohtsu A, et al. A randomized, open label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol. 2016;34(suppl4S):abstract 5.CrossRef
3.
Zurück zum Zitat Janjigian YY, Bendell JC, al Calvo Eet. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol. 2016;34(suppl):abstract 4010.CrossRef Janjigian YY, Bendell JC, al Calvo Eet. CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC). J Clin Oncol. 2016;34(suppl):abstract 4010.CrossRef
4.
Zurück zum Zitat Finn RS, Martin M, Hope S, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breats cancer (ABC). J Clin Oncol. 2016;34(suppl):abstract 524. Finn RS, Martin M, Hope S, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2- advanced breats cancer (ABC). J Clin Oncol. 2016;34(suppl):abstract 524.
5.
Zurück zum Zitat Planchard D, Besse B, Groen HJM, et al. An open-label phase II trial of dabrafenib (D) in combination with rametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol. 2016;34(suppl):abtract 107.CrossRef Planchard D, Besse B, Groen HJM, et al. An open-label phase II trial of dabrafenib (D) in combination with rametinib (T) in patients (pts) with previously treated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC; BRF113928). J Clin Oncol. 2016;34(suppl):abtract 107.CrossRef
6.
Zurück zum Zitat Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+NSCLC): primary results from the J‑ALEX study. J Clin Oncol. 2016;34(suppl):abstract 9008.CrossRef Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+NSCLC): primary results from the J‑ALEX study. J Clin Oncol. 2016;34(suppl):abstract 9008.CrossRef
7.
Zurück zum Zitat Mir O, Brodowicz T, Wallet J, et al. Activity of Regorafenib in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): results of a double-blind, randomized placebo (PL) controlled phase II trial. J Clin Oncol. 2016;34(suppl):abstract 10504. Mir O, Brodowicz T, Wallet J, et al. Activity of Regorafenib in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): results of a double-blind, randomized placebo (PL) controlled phase II trial. J Clin Oncol. 2016;34(suppl):abstract 10504.
8.
Zurück zum Zitat Vennok AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CAGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl):abstract 3504.CrossRef Vennok AP, Niedzwiecki D, Innocenti F, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CAGB/SWOG 80405 (Alliance). J Clin Oncol. 2016;34(suppl):abstract 3504.CrossRef
Metadaten
Titel
ASCO update 2016
verfasst von
Wolfgang Eisterer
Publikationsdatum
01.12.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0301-5

Weitere Artikel der Ausgabe 4/2016

memo - Magazine of European Medical Oncology 4/2016 Zur Ausgabe